Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index (HSSCPB) decreased by 1.63% as of August 8, 2025, with mixed performance among constituent stocks [3] - The top-performing stocks included CSPC Pharmaceutical Group (up 4.44%), United Laboratories (up 3.29%), and Kangji Medical Holdings (up 1.38%), while the worst performers were Hutchison China MediTech (down 15.70%), Zai Lab (down 10.86%), and BeiGene (down 6.47%) [3] - The Hong Kong Stock Connect Innovative Drug Selected ETF (520690) fell by 1.64%, with the latest price at 0.96 yuan [3] Group 2 - The pharmaceutical and biotechnology sector received a policy boost with the release of measures to support high-quality development of innovative drugs in July 2025, leading to a significant increase of 13.93% in the sector [4] - The latest share count for the Hong Kong Stock Connect Innovative Drug Selected ETF reached 360 million, a new high since its inception [4] - Recent net inflows into the ETF amounted to 4.92 million yuan, with a total of 32.45 million yuan net inflow over the last five trading days [4] Group 3 - The top ten weighted stocks in the HSSCPB index accounted for 78.03% of the total index weight, including companies like BeiGene, Innovent Biologics, and WuXi Biologics [6]
港股创新药精选ETF(520690)近5日净流入超3200万元，石药集团涨超4%，创新药政策支持窗口备受关注